Having trouble viewing this email? Click here.

facebook twitter linkedin Like Lundbeck Announces Date of ONFI (Clobazam) Tablet Availability in the United States | Dravet.org News on Facebook

(443) 607-8267

P.O. Box 797
Deale, MD 20751

News Update December 2011

Lundbeck Announces Date of ONFI™ (Clobazam) Tablet Availability in the United States

Lundbeck, the manufacturer of ONFI, an oral anti-epileptic drug (AED) of the benzodiazepine class, has announced that the drug will be made available for prescribing in the United States on January 3, 2012. ONFI (clobazam) is a prescription medicine used along with other medicines to treat seizures associated with Lennox-Gastaut syndrome (LGS) in people two years of age or older.

Dravet.org Announces Date of 2012 Conference
The Dravet.org 2012 Family Medical Conference will be held Thursday, August 16 through Sunday, August 19 in Bloomington, Minnesota, near the Mall of America which features an indoor amusement park, a walk-through aquarium, and much more.

Save $200 on Emfit Epilepsy Monitors and Earn Money for Dravet.org!
If you've been thinking about buying an Emfit epilepsy monitor, now is the perfect time to do it. Through the end of December, Emfit monitors purchased through the company's website or by phone are available for $400 instead of the regular price of $600 -- the deepest discount Emfit has ever offered for their monitors.

But there's more. If you mention us by name, Emfit will make a $40 contribution to Dravet.org!

Here's how it works: to order online, visit the Emfit epilepsy monitor web page and click the "Buy Now" button. When you check out, type "HOLIDAY SPECIAL" in the coupon code section. Then, in the comments section, type "Dravet.org referred us." That's it!

Thanks to Emfit, you can help Dravet.org raise money for its educational, advocacy, research, and support mission while also saving money on the purchase of an Emfit monitor for your child

Callout Top
Dravet.org is constantly updating our website with the latest news in medical research, study updates, scientific articles, and related events. Below are just a few of the scientific articles posted on Dravet.org. Click on each title to read the entire article and be sure to check www.dravet.org regularly for the latest news updates!
Callout Bottom

New Dravet Syndrome Causative Gene Candidate, Insights into Dravet Mechanisms Announced
Research presented at the American Epilepsy Society’s 65th Annual Meeting revealed a new candidate gene for Dravet syndrome other than the sodium ion channel SCN1A, the GABA-receptor gene GABRA1. It was also announced that scientists have been able to reprogram fibroblasts from Dravet patients to generate patient-specific neurons that can be tested to identify the physiological mechanism that drives Dravet syndrome, and the anticonvulsant drug bromide, which is not FDA-approved for use in the United States, may have promise in treating patients with SCN1A-associated Dravet syndrome with intractable seizures.

More Details on Fibroblasts for Dravet Characterization

Researchers from the University of Michigan have discovered a way to reprogram fibroblasts (a type of skin cell) taken from patients with Dravet syndrome to generate neurons that are specific to the individual patient. They hope to eventually be able to use these neurons in the preparation of new therapies and medications to treat Dravet syndrome.

Details on ONFI Trials that Led to FDA Approval

At the American Epilepsy Society's 65th Annual Meeting in Baltimore, Maryland on December 26, 2011), five poster sessions highlighted the clinical trials that led to the approval of the antiepileptic drug ONFI (clobazam) for use as an adjunct therapy in the treatment of Lennox Gastaut Syndrome (LGS).

Donate Btn

Helping the Patient While Finding the Cure

If someone you know needs our help and information, please let them know of our support services. And please consider making a generous donation so we can help more families and fund more research.